clinical trial · NCT04683250
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Taiho Pharmaceutical Co., Ltd.·phase2·recruiting·n = 244
RET-altered Non Small Cell Lung CancerRET-altered Solid TumorsTAS0953/HM06TAS0953/HM06
brief summary
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
started
Dec 16, 2020
primary completion
Mar 1, 2030
completion
Mar 1, 2031
last updated
Mar 3, 2026
official title
Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol